Endo Reports Fourth Quarter And Full Year 2015 Financial Results

Go back to Endo Reports Fourth Quarter And Full Year 2015 Financial Results

Mizuho Securities Remains Sidelined Following Endo Int'l's (ENDP) Mixed 4Q Results

March 2, 2016 7:10 AM EST

Mizuho Securities reiterated a Neutral rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $42.00 (from $55.00), following the company's 4Q earnings report. ENDP reported revenues of $1.07B, in-line with consensus' estimate. EPS was reported at $1.36, ahead of expectations of $1.27. ENDP introduced... More

Piper Jaffray Remains Bullish on Endo Int'l (ENDP) Following an In-Line 4Q - PT to $81

March 1, 2016 9:04 AM EST

Piper Jaffray maintained an Overweight rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $81.00 (from $83.00), following the company's relatively in-line 4Q earnings results. Endo reported 4Q15 non-GAAP EPS of $1.36 on revenues of $1.1B. Sales of Xiaflex in 4Q15 were $50M, up 26% versus 3Q15 sales of $40M, with ENDP citing... More

Leerink Partners Cuts Price Target on Endo Int'l (ENDP) Following 4Q Earnings Report

March 1, 2016 7:50 AM EST

Leerink Partners maintained an Outperform rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $51.00 (from $64.00), following the company's 4Q earnings report. ENDP generics were unfavorably impacted by increased pricing pressure in pain and commodity products within legacy Qualitest, an... More

Endo Int'l (ENDP) Tops Q4 EPS by 9c; Guides FY16 EPS

February 29, 2016 6:34 AM EST

Endo Int'l (NASDAQ: ENDP) reported Q4 EPS of $1.36, $0.09 better than the analyst estimate of $1.27. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.07 billion.

GUIDANCE:

Endo Int'l sees FY2016 EPS of $5.85-$6.20, versus the consensus of... More